FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043350897> ?p ?o ?g. }

• W3043350897 abstract "ABSTRACT Background At least 1 in 6 COVID-19 patients admitted to hospital and receiving supplemental oxygen will die of complications. More than 50% of patients with COVID-19 that receive invasive treatment such as mechanical ventilation will die in hospital. Such impacts overwhelm the limited intensive care unit resources and may lead to further deaths given inadequate access to care. Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at a pressure higher than 1.4 atmosphere absolute (ATA). HBOT is safe, including for lungs, when administered by experienced teams and is routinely administrated for a number of approved indications. Preliminary clinical evidence suggests clinical improvement when hypoxemic COVID-19 patients are treated with HBOT. Objective We aim to determine the effectiveness of HBOT for improving oxygenation, morbidity, and mortality among hypoxemic COVID-19 patients. Methods and analysis This trial is a sequential Bayesian Parallel-group, individually Randomized, Open, Blinded Endpoint controlled trial. Admitted hypoxemic COVID-19 patients who require supplemental oxygen (without mechanical ventilation) to maintain a satisfying tissue oxygenation will be eligible to participate. The anticipated sample size of 234 patients is informed by data from a treatment trial of COVID patients recently published. The intervention group will receive one HBOT per day at 2.0 ATA for 75 minutes. Daily HBOT will be administered until the patient does not require any oxygen supplementation, requires any type of mechanical ventilation, or until day 10 of treatment. Patients in the control group will receive the current standard of care treatment (no HBOT). The primary outcome of this trial will be the 7-level COVID ordinal outcomes scale assessed on Day 7 post-randomization. Secondary outcomes will include: (a) clinical outcomes (length of hospital stay, days with oxygen supplementation, oxygen flow values to obtain a saturation by pulse oximetry ≥90%, intensive care admission and length of stay, days on invasive mechanical ventilation, sleep quality, fatigue, major thrombotic events, the 7-level COVID ordinal outcomes scale on Day 28; mortality, safety); (b) biological outcomes (plasma inflammatory markers); and (c) health system outcomes (cost of care and cost-effectiveness). Predetermined inclusion/exclusion criteria have been specified. The analytical approach for the primary outcome will use a Bayesian proportional odds ordinal logistic semiparametric model. The primary analysis will be by intention-to-treat. Bayesian posterior probabilities will be calculated every 20 patients to assess accumulating evidence for benefit or harm. A planned subgroup analysis will be performed for pre-specified variables known to impact COVID-19 prognosis and/or HBOT (biologic sex and age). Discussion Based on the mortality rate and substantial burden of COVID-19 on the healthcare system, it is imperative that solutions be found. HBOT is a non-invasive and low-risk intervention when contraindications are respected. The established safety and relatively low cost of providing HBOT along with its potential to improve the prognosis of severe COVID-19 patients make this intervention worth studying, despite the current limited number of HBOT centres. If this trial finds that HBOT significantly improves outcome and prevents further deterioration leading to critical care for severe COVID-19 patients, practice will change internationally. If no benefit is found from the intervention, then the current standard of care (no HBOT) will be supported by level I evidence. Trials Registration NCT04500626" @default.
• W3043350897 created "2020-07-23" @default.
• W3043350897 creator A5002876858 @default.
• W3043350897 creator A5015513110 @default.
• W3043350897 creator A5018366336 @default.
• W3043350897 creator A5021691260 @default.
• W3043350897 creator A5022373677 @default.
• W3043350897 creator A5022700654 @default.
• W3043350897 creator A5024743010 @default.
• W3043350897 creator A5027378826 @default.
• W3043350897 creator A5028079374 @default.
• W3043350897 creator A5036161954 @default.
• W3043350897 creator A5051508109 @default.
• W3043350897 creator A5053849841 @default.
• W3043350897 creator A5056070467 @default.
• W3043350897 creator A5062197885 @default.
• W3043350897 creator A5063730593 @default.
• W3043350897 creator A5067518918 @default.
• W3043350897 creator A5068267152 @default.
• W3043350897 creator A5069673392 @default.
• W3043350897 creator A5070564381 @default.
• W3043350897 creator A5078027320 @default.
• W3043350897 creator A5079269066 @default.
• W3043350897 creator A5080607592 @default.
• W3043350897 creator A5081648256 @default.
• W3043350897 creator A5082483103 @default.
• W3043350897 creator A5091262277 @default.
• W3043350897 date "2020-07-16" @default.
• W3043350897 modified "2023-09-23" @default.
• W3043350897 title "Protocol for a multicentre randomized controlled trial of normobaric versus hyperbaric oxygen therapy for hypoxemic COVID-19 patients" @default.
• W3043350897 cites W1896805399 @default.
• W3043350897 cites W2111308825 @default.
• W3043350897 cites W2112849005 @default.
• W3043350897 cites W2115709314 @default.
• W3043350897 cites W2169300691 @default.
• W3043350897 cites W2470843373 @default.
• W3043350897 cites W2967363897 @default.
• W3043350897 cites W2996400124 @default.
• W3043350897 cites W3008307061 @default.
• W3043350897 cites W3008827533 @default.
• W3043350897 cites W3009885589 @default.
• W3043350897 cites W3012379316 @default.
• W3043350897 cites W3013816672 @default.
• W3043350897 cites W3015053717 @default.
• W3043350897 cites W3015622688 @default.
• W3043350897 cites W3016636325 @default.
• W3043350897 cites W3018517500 @default.
• W3043350897 cites W3021839904 @default.
• W3043350897 cites W3030068155 @default.
• W3043350897 doi "https://doi.org/10.1101/2020.07.15.20154609" @default.
• W3043350897 hasPublicationYear "2020" @default.
• W3043350897 type Work @default.
• W3043350897 sameAs 3043350897 @default.
• W3043350897 citedByCount "3" @default.
• W3043350897 countsByYear W30433508972021 @default.
• W3043350897 countsByYear W30433508972022 @default.
• W3043350897 crossrefType "posted-content" @default.
• W3043350897 hasAuthorship W3043350897A5002876858 @default.
• W3043350897 hasAuthorship W3043350897A5015513110 @default.
• W3043350897 hasAuthorship W3043350897A5018366336 @default.
• W3043350897 hasAuthorship W3043350897A5021691260 @default.
• W3043350897 hasAuthorship W3043350897A5022373677 @default.
• W3043350897 hasAuthorship W3043350897A5022700654 @default.
• W3043350897 hasAuthorship W3043350897A5024743010 @default.
• W3043350897 hasAuthorship W3043350897A5027378826 @default.
• W3043350897 hasAuthorship W3043350897A5028079374 @default.
• W3043350897 hasAuthorship W3043350897A5036161954 @default.
• W3043350897 hasAuthorship W3043350897A5051508109 @default.
• W3043350897 hasAuthorship W3043350897A5053849841 @default.
• W3043350897 hasAuthorship W3043350897A5056070467 @default.
• W3043350897 hasAuthorship W3043350897A5062197885 @default.
• W3043350897 hasAuthorship W3043350897A5063730593 @default.
• W3043350897 hasAuthorship W3043350897A5067518918 @default.
• W3043350897 hasAuthorship W3043350897A5068267152 @default.
• W3043350897 hasAuthorship W3043350897A5069673392 @default.
• W3043350897 hasAuthorship W3043350897A5070564381 @default.
• W3043350897 hasAuthorship W3043350897A5078027320 @default.
• W3043350897 hasAuthorship W3043350897A5079269066 @default.
• W3043350897 hasAuthorship W3043350897A5080607592 @default.
• W3043350897 hasAuthorship W3043350897A5081648256 @default.
• W3043350897 hasAuthorship W3043350897A5082483103 @default.
• W3043350897 hasAuthorship W3043350897A5091262277 @default.
• W3043350897 hasBestOaLocation W30433508971 @default.
• W3043350897 hasConcept C126322002 @default.
• W3043350897 hasConcept C141071460 @default.
• W3043350897 hasConcept C168563851 @default.
• W3043350897 hasConcept C177713679 @default.
• W3043350897 hasConcept C194828623 @default.
• W3043350897 hasConcept C203092338 @default.
• W3043350897 hasConcept C2776376669 @default.
• W3043350897 hasConcept C2777080012 @default.
• W3043350897 hasConcept C2779134260 @default.
• W3043350897 hasConcept C2780807750 @default.
• W3043350897 hasConcept C3008058167 @default.
• W3043350897 hasConcept C42219234 @default.
• W3043350897 hasConcept C524204448 @default.
• W3043350897 hasConcept C535046627 @default.
• W3043350897 hasConcept C71924100 @default.
• W3043350897 hasConceptScore W3043350897C126322002 @default.
• W3043350897 hasConceptScore W3043350897C141071460 @default.

• next